Following today’s High Court ruling by Mr Justice Green on the commissioning of Pre-Exposure Prophylaxis (PrEP) and the subsequent appeal of this ruling by NHS England, the Association of the British Pharmaceutical Industry (ABPI) has responded calling for a commissioning process that is fair, consistent and transparent.
01 Aug 2016 Posted in News Release By Press Office
Pending a decision from the Court of Appeal on Justice Green's ruling, NHS England have announced that:
Mike Thompson, Chief Executive of the ABPI, said:
"Consistency and clarity for the commissioning of medicines is vital. Patients and their families will now only face further delay in accessing a number of treatments for HIV, cystic fibrosis, cancer, and other life-changing medicines that continue to be clogged up in the system.
NHS England and drugs companies must now find a way to ensure the very latest medical innovations get to the patients who need them as quickly and as efficiently as possible, and this must be done within a commissioning process that is fair, consistent and transparent.
Everyone is acutely aware that there isn't much spare cash in the NHS coffers, and our members already play their part in helping to meet budgets. We need to strike a sensible balance and ensure that both the NHS and the companies researching and discovering new medicines receive fair and appropriate value."
ABPI Press Office
Telephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441
Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies supplying around 90 per cent of all medicines used by the NHS, and are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.